Treatment of multiple sclerosis and neuromyelitis optica
AssigneeOklahoma Medical Research Foundation
InventorRobert C. AXTELL
Life of this patent
Estimating the term…
Abstract
The present disclosure provides for the diagnosis and prediction of neuromyelitis optica (NMO) in subject. It also provides for treatment of multiple sclerosis (MS) in a subject. Thus, in accordance with the present disclosure, there is provided a method for treating a subject having neuromyelitis optica (NMO) comprising administering to said subject an inhibitor of B-cell activating factor (BAFF) and/or an inhibitor or proliferating inducing ligand (APRIL).
Claims31
A method for treating a subject having neuromyelitis optica (NMO) comprising administering to said subject an inhibitor of B-cell activating factor (BAFF) and/or an inhibitor or proliferating inducing ligand (APRIL).
2-9. (canceled)
(canceled)
(canceled)
A method for treating a subject having interferon-resistant multiple sclerosis (MS) comprising administering to said subject an inhibitor of B-cell activating factor (BAFF) and/or an inhibitor or proliferating inducing ligand (APRIL).
17-24. (canceled)
(canceled)
(canceled)
A method of identifying a subject having multiple sclerosis (MS) that will be resistant to interferon therapy comprising:
- (a) obtaining a sample from said subject;
- and
- (b) assessing levels of a TH17/granulocyte factor, a type 1 interferon, B-cell activating factor (BAFF) and/or proliferating inducing ligand (APRIL) in said sample,
- wherein a subject having elevated TH17/granulocyte factors, type 1 interferons, BAFF and/or APRIL levels will not respond to interferon therapy.
34-35. (canceled)
37-44. (canceled)
(canceled)
50-55. (canceled)
57-59. (canceled)
Dependencies are inferred from the claim text.